ArticleBMC cancer2024

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.

Alessio Cirillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.